Loading organizations...
Key people at Unicorn Capital.
Unicorn Capital was founded in 2015 by Kah Fai Low (Co-Founder & Managing Partner) and Tommy Yip (Founder & Managing Partner).
Unicorn Capital Partners operates a dedicated fund-of-funds platform, specializing in venture capital fund and direct investment opportunities. The firm strategically allocates capital within the Chinese market, focusing on high-potential enterprises and underlying funds. Its approach involves rigorous due diligence to identify and support innovative ventures.
Co-founded in 2015 by Yan Chak Tommy Yip and Kah Fai Low, Unicorn Capital Partners emerged from an understanding of China's expanding venture landscape. Both Managing Partners leverage experience to shape the firm’s investment strategy. Tommy Yip’s background as Partner and Head of North Asia at Emerald Hill Capital Partners underscores their established pedigree.
The firm serves institutional investors seeking strategic exposure to the Chinese venture ecosystem, while providing crucial capital to promising growth companies. Unicorn Capital Partners envisions itself as a leading facilitator of capital into China's innovation economy, aiming to generate significant value through its network and market insights.
Key people at Unicorn Capital.
Unicorn Capital was founded in 2015 by Kah Fai Low (Co-Founder & Managing Partner) and Tommy Yip (Founder & Managing Partner).
Unicorn Capital has 2 tracked investments across 2 companies. The latest tracked deal is $180.0M Series C in Bluejay Therapeutics in May 2024.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2024 | Bluejay Therapeutics | $180.0M Series C | Daniel Estes | Eric Shiozaki, Digitalis Ventures, Frazier Healthcare Partners, Rivervest, Westlake Village BioPartners, Arkin BIO Ventures, HBM Healthcare Investments, Novo Holdings, Octagon Capital, RA Capital Management, RiverVest Venture Partners, T. Rowe Price Associates, Wellington Management |
| Mar 27, 2023 | ArriVent Biopharma | $155.0M Series B | Elena Viboch, James Healy | Aihc Capital, Catalio Capital, HBM Healthcare Investments, Hongshan Capital Group (Sequoia Capital China), Infinitum Asset Management, Lilly Asia Ventures, Octagon Capital, Carl Gordon, Shanghai Healthcare Capital, Sirona Capital, Terra Magnum Capital Partners, ZOO Capital |